Spyre Therapeutics, Inc.

The US Food and Drug Administration’s prescription drug user fee goal date calendar for May may be overshadowed by the 31 May goal date for Moderna ’s next-generation COVID-19 vaccine, given a resurg

Private investment in public equity (PIPE) transactions continue to be an important means of fundraising for publicly traded biopharmaceutical companies while the financial markets continue to recover

The US first-approver advantage over the European Union remains stark, with eight of ten novel agents first cleared by the US Food and Drug Administration, according to a Pink Sheet analysis of rece

Soon-to-be public Oruka Therapeutics will execute a reverse merger with ARCA Biopharma, Inc. and a concurrent $275m financing to help it start clinical development of optimized biologics in psoria